We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Why Organs Fail Following Massive Trauma

By HospiMedica staff writers
Posted on 03 Nov 2006
A new study has found several new biochemical pathways that play a central role in multiple organ failure following severe trauma.

Researchers from eight universities, led by a team from the University of Rochester Medical Center (NY, USA), took blood samples from 22 healthy subjects and from 18 consenting patients who had experienced severe trauma and were in the midst of organ failure. More...
The researchers then used unique, clinically applicable techniques to separate out each immune cell type in the patients' blood into pure samples for study. Next they used microarray technology to generate a long list of genes that change when a patient undergoes massive trauma. They ran that list through a database of genetic information to see which of the genes changed by trauma were listed in the literature as having a role in T cell function. What emerged was a map of the likely functions of hundreds of genes and proteins related to T cell post-trauma dysfunction and their likely partners in signaling pathways.

Results showed that the expression of nearly 5,700 genes related to T cell function is changed in cases of massive trauma, as are 2,800 genes related to the function of macrophages, partnering immune cells necessary to T cell activation. Trauma had the most profound effect on just 338 of the genes, who showed at least a two-fold change in their expression. Post-traumatic genetic changes had two major effects on T cells: a marked increase in regulatory protein pathways that diminished their function, and a decrease in signals that turn them on.

Whether T cells continue to multiply depends on the action of sensitive receptor proteins on their surfaces. Some of the receptors, once activated by signaling molecules, cause the T cell to multiply, while others stop the process or cause the cell to self-destruct. Researchers in the current study identified as many as 20 new receptors on the surfaces of T cells or signaling molecules within T cells that increase their activity in the case of massive trauma to either cause anergy or apoptosis. Each pathway represents a target for the design of new drugs to reverse T cell shutdown.

"Our study proves for the first time that it is possible to identify the genetic and protein changes in specific immune cells that play a significant role in determining whether or not trauma is fatal,” said co-author Carol L. Miller-Graziano, Ph.D., a professor of surgery, and of microbiology and immunology at the University of Rochester. "Beyond trauma, we believe that the techniques established here can provide insights into many diseases that involve human immune system failure.”

The study was published in the October 17, 2006 issue of the Proceedings of the [U.S.] National Academy of Sciences (PNAS).



Related Links:
University of Rochester Medical Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.